A Partnership Built to Succeed

By joining forces, Public Health Vaccines, LLC and Crozet BioPharma, LLC are applying their collective vaccine expertise to build a safe and effective novel vaccine against Nipah virus disease, with funding from CEPI.

Our goal is to develop a single-dose Nipah vaccine that is well-tolerated and effective by employing novel technologies and product development strategies to address this major unmet public health need. In the World Health Organization R&D Blueprint, Nipah has been named a priority diseases for fast track vaccine development.

Public Health Vaccines, LLC

Crozet BioPharma

CEPI

Nipah by the Numbers

Frequently Asked Questions

Check out our FAQ page for answers to the most frequently asked questions about the Nipah virus and our vaccine project.

 
 

A Novel Vaccine Development Method

The Nipah vaccine being developed by PHV and Crozet uses recombinant DNA technology. Like many of the most successful vaccines used to protect against infectious diseases (e.g. measles, mumps, German measles, chickenpox, smallpox, oral polio, rotavirus, yellow fever), the recombinant vaccine against Nipah is a live, replication competent vaccine, engineered to balance safety and effectiveness.

Latest News

May 1, 2020

How Fighting Nipah Helped KK Shailaja Fight Covid-19

KK Shailaja, Health Minister for the Indian state of Kerala, used her knowledge of fighting the Nipah virus to prepare her state for the Coronavirus.
April 1, 2020
Dr Emily Gurley. Photo JHU

Tracking the Nipah Virus

Dr Emily Gurley's 20 year quest to understand and prevent Nipah’s spread from bats to humans.
March 1, 2020

The Next Pandemic is Already Coming

Leading scientists discuss the epidemic potential of person to person spread of Nipah virus disease.
One Health Initiative